

Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance

Running head: Biologic characterization of MRD myeloma cells

Authors: Bruno Paiva ¹, Luis A. Corchete ², Maria-Belen Vidriales ², Noemi Puig ², Patricia Maiso ¹, Idoia Rodriguez ¹, Diego Alignani ¹, Leire Burgos ¹, Maria Luz Sanchez ³, Paloma Barcena ³, Maria-Asuncion Echeveste ⁴, Miguel T. Hernandez ⁵, Ramón García-Sanz ², Enrique M. Ocio ², Albert Oriol ⁶, Mercedes Gironella ⁷, Luis Palomera ⁸, Felipe De Arriba ⁹, Yolanda Gonzalez ¹⁰, Sarah K. Johnson ¹³, Joshua Epstein ¹³, Bart Barlogie ¹³, Juan-Jose Lahuerta ¹¹, Joan Blade ¹², Alberto Orfao ³, María-Victoria Mateos ² and Jesús F San Miguel ¹, on behalf of GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study groups.

Author Affiliations: (1) Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), IDISNA, Pamplona; (2) Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC), Salamanca; (3) Servicio General de Citometría, Centro de Investigación del Cancer (IBMCC-USAL, CSIC), IBSAL and Department of Medicine, Universidad de Salamanca. Salamanca; (4) Hospital de Donostia, San Sebastian; (5) Hospital Universitario de Canarias, Tenerife; (6) Hospital Universitari Germans Trias i Pujol, Badalona; (7) Hospital Vall de Hebron, Barcelona; (8) Hospital Lozano Blesa, Zaragoza; (9) Hospital Morales Meseguer, Murcia; (10) Hospital Universitario Josep Trueta, Girona; (11) Hospital 12 de Octubre, Madrid; (12) Hospital Clínic, IDIBAPS, Barcelona. Spain. (13) Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR.

Corresponding author

Jesus F. San Miguel, M.D.,Ph.D.

Clinica Universidad de Navarra; Centro de Investigacion Médica Aplicada (CIMA)

Av. Pio XII 36, 31008 Pamplona, Spain

e-mail: sanmiguel@unav.es

Abstract

Persistence of chemoresistant minimal residual disease (MRD) plasma cells (PCs) is associated with inferior survival in multiple myeloma (MM). Thus, characterization of the minor MRD subclone may represent a unique model to understand chemoresistance but to our knowledge, the phenotypic and genetic features of the MRD subclone have never been investigated. Here, we compared the antigenic profile of MRD vs. diagnostic clonal PCs in 40 elderly MM patients enrolled in the GEM2010MAS65 study, and showed that the MRD subclone is enriched in cells over-expressing integrins (CD11a/CD11c/CD29/CD49d/CD49e), chemokine receptors (CXCR4) and adhesion molecules (CD44/CD54). Genetic profiling of MRD vs. diagnostic PCs was performed in twelve patients; three of them showed identical copy number alterations (CNAs), in other three cases MRD clonal PCs displayed all genetic alterations detected at diagnosis plus additional CNAs that emerged at the MRD stage, whereas in the remaining six patients there were both CNAs present at diagnosis that were undetectable in MRD clonal PCs, but also a selected number of genetic alterations that became apparent only at the MRD stage. The MRD subclone showed significant downregulation of genes related to protein processing in endoplasmic reticulum, as well as novel deregulated genes such as *ALCAM* that is prognostically relevant in MM and may identify chemoresistant PCs *in vitro*. Altogether, our results suggest that therapy-induced clonal selection could be already present at the MRD stage, where chemoresistant PCs show a singular phenotypic signature that may result from the persistence of clones with different genetic and gene expression profiles.

Key points:

- We report for the first time the biologic features of MRD cells in MM and unravel that clonal selection is already present at the MRD stage
- MRD cells show a singular phenotypic signature that may result from persisting clones with different genetic and gene expression profiles

Introduction

In multiple myeloma (MM) as in virtually all hematologic malignancies there is a correlation between depth of response and prolonged survival.¹ Over the past 20 years, significantly higher rates of complete response (CR) have been achieved contributing to improve MM patients' outcome.² However, long-term follow-up studies have shown that approximately two thirds of these will not sustain their CR, and relapse before they can be considered as achieving "operational cure" (i.e.: more than 10-years progression-free survival).³ Relapses among MM patients in CR are now better understood and predicted with the advent of minimal residual disease (MRD) studies, which have shown an intrinsic correlation between the persistence of reduced numbers of clonal plasma cells (PCs) after therapy (i.e.: MRD) and inferior survival.⁴⁻⁷ Thus, MRD represents a very small fraction of all diagnostic tumor cells which are chemoresistant, potentially quiescent (not producing M-protein), and able to recapitulate the initial tumor burden at relapse.

Overall, there are two putative mechanisms by which chemoresistance may arise in cancer; i) therapy-induced molecular alterations, and ii) presence of cellular heterogeneity within the tumor bulk where several subclones coexist and compete with each other in such a way that treatment eradicates the major subclone (chemosensitive), but a minor, resistant and initially dormant subclone subsequently expands and gives rise to disease relapse.⁸ In MM, the first mechanism has been suggested to explain chemoresistance to proteasome inhibition (e.g.: acquired mutations in genes encoding proteasome beta subunits⁹ or decreased endoplasmic reticulum –ER- stress signaling¹⁰) and immunomodulatory agents (e.g.: decreased cereblon expression^{11,12}, over-expression hyaluronan binding proteins such as CD44¹³), or upregulation of the MEK/ERK pathway.¹⁴ In turn, the second mechanism would explain the shift in dominance of tumor subclones over time in paired samples from MM patients studied at diagnosis vs. relapse.¹⁵⁻¹⁷ Of note, chemoresistance may also result from the combination of both mechanisms; for example, when less differentiated myeloma PC clones down-regulate specific transcriptional factors to overcome treatment (e.g.: suppression of Xbp1s to diminish ER front-loading and cytotoxic susceptibility to proteasome inhibition).¹⁸ Despite all the above, both hypothetical mechanisms rely on data generated from the study of clonal PCs at the time of relapse, while no biologic studies have been performed in primary chemoresistant clonal PCs that persist at MRD levels after frontline therapy before the patients' relapse.

MRD monitoring has become one of the most relevant prognostic factors in MM, independently of patients' serological response and diagnostic cytogenetic profile.⁵ Thus, it has been shown that the outcome of patients with standard- or high-risk

cytogenetics is modulated by the persistence vs. eradication of MRD ⁵ but also that, particularly among MRD-positive cases, survival is significantly inferior in patients with clonal PCs harboring high-risk cytogenetic abnormalities.⁵ Thus, both the depth of response and the genetic profile of chemoresistant subclones most likely play an important role in the outcome of MM patients. Thereby, a better understanding of the biologic signature of MRD vs. diagnostic cells could potentially contribute to gain insight in the mechanisms of chemoresistance at the MRD level, and the potential discovery of novel therapeutic targets.

Here, we have characterized chemoresistant MRD cells from patients included in the GEM2010MAS65 clinical trial, by comparing their phenotypic and genetic profiles against paired diagnostic clonal PCs. Our results reveal that therapy-induced clonal selection is already present at the MRD stage, in which chemoresistant PCs show a singular phenotypic signature that may result from the persistence of clones with different cytogenetic and gene expression profiles. Furthermore, we show that such analyses also provide a novel approach to better understand chemoresistance, through the identification of novel candidate genes which could be potentially responsible for drug resistance and consequently, impact on patients' survival.

Methods.

Patients and treatment. A total of 40 elderly, transplant-ineligible patients with newly-diagnosed symptomatic MM staged according to the International Myeloma Working Group criteria¹⁹ were prospectively studied after inclusion in the GEM2010MAS65 trial (NCT01237249). In all patients, bone marrow (BM) aspirates were collected at diagnosis and after nine cycles of induction therapy. In brief, patients treatment consisted of either nine identical induction cycles with bortezomib, melphalan, prednisone (VMP; n=21), or alternating cycles of VMP and lenalidomide plus low-dose dexamethasone (Rd) for up to nine courses (n=19). Samples were collected after informed consent was given by each individual according to the local ethical committees and the Helsinki Declaration.

Multidimensional flow cytometry (MFC) immunophenotyping. Approximately 400µL of EDTA-anticoagulated BM aspirated samples were immunophenotyped using four different 8-color combinations of monoclonal antibodies (MoAb) direct immunofluorescence stain-and-then-lyse technique: [Pacific Blue (PacB), Pacific Orange (PacO), fluorescein isothiocyanate (FITC), phycoerythrin (PE), peridinin chlorophyll protein-cyanin 5.5 (PerCP-Cy5.5), PE-cyanin 7 (PE-Cy7), allophycocyanin (APC), alexafluor 700 (AF700)]: i) CD29, CD45, CD11a, β 7, CD79b, CD49d, CD19, CD38; ii) CD11c, CD45, CD41a, CD49e, CD33, CD117, CD19, CD38; iii) CD20, CD45, CD81, CD54, CD138, CD56, CD19, CD38, and; iv) HLA-DR, CD45, CD44, CXCR4, CD27, CD28, CD19, CD38. Markers were selected based on their role to identify the PC compartment (CD38, CD138), discriminate clonal from normal PCs within the PC compartment (CD19, CD20, CD27, CD28, CD45, CD56, CD81, CD117), define B-cell/PC differentiation (CD19, CD20, CD27, CD45, CD79b, CD81, HLADR), to mediate cell-to-cell interactions (CD28, CD117), and in cell-adhesion-mediated-drug-resistance (CAM-DR: CD11a, CD11c, CD29, CD41a, CD44, CD49d, CD49e, CD54, CXCR4, β 7). Data acquisition was performed for approximately 10^6 leukocytes/tube in a FACSCantoll flow cytometer (Becton Dickinson Biosciences – BDB – San Jose, CA) using the FACSDiva 6.1 software (BDB). Instrument performance was daily monitored using the Cytometer Setup Tracking (CST; BDB) and rainbow 8-peak beads (Spherotech, Inc; Lake Forest, IL) after laser stabilization, following the EuroFlow guidelines²⁰; sample acquisition was performed only in case of longitudinal instrument stability. In Supplementary Figure 1, the expression levels of CD19 in mature B-cells from BM samples assessed at diagnosis and after induction are represented, and confirm the longitudinal instrument stability. Per protocol, newly-diagnosed MM patients

included in the GEM2010MAS65 trial had BM samples studied after 9 induction cycles to monitor MRD levels; whenever persistent clonal PCs were detected (MRD-positive), exactly the same immunophenotypic method performed at diagnosis was repeated for the characterization of the chemoresistant clone after therapy.

Generation of immunophenotypic protein expression profiles (iPEP). To generate iPEPs, we used first those five parameters measured in common for each aliquot (CD38, CD45, CD19, forward light scatter –FSC- and sideward light scatter –SSC-) to define the PC compartment. Then, the iPEP of diagnostic (baseline) and chemoresistant (MRD) cells for all 23 phenotypic markers analyzed plus FSC and SSC was generated for every single clonal PC, after merging of flow cytometry data files and calculation of data.^{21,22} First, the merge function of the Infinicyt software (Cytognos SL, Salamanca, Spain) was used to fuse the different data files corresponding to the 4 different 8-color MoAb combinations studied per sample, into a single data file containing all information measured for that sample. For any single cell in each 8-color MoAb combination (aliquot), this included data about those antigens that were measured directly on it and antigens which were not evaluated directly (“missing values”) for that cell in the corresponding aliquot it was contained in. Then, the calculation function of the Infinicyt software was used to fill in the “missing values”, based on the “nearest neighbor” statistical principle^{23,24}, defined by the unique position (Euclidean distance) of individual PCs in the multidimensional space created by the five common (backbone) parameters (FSC, SSC, CD38, CD45 and CD19). The “nearest neighbor” for each individual clonal PC in a sample aliquot was calculated as that clonal PC in another aliquot showing the shortest distance to it in the three-dimensional space generated by the five parameters measured in common in both aliquots. Then, for each individual single clonal PCs in a sample aliquot, those values obtained for each of the closest single clonal PC in the other aliquot were assigned for each of those parameters not actually measured in the former single clonal PC.^{25,26} Ultimately, an iPEP was generated for every single PC, which included all 23 phenotypic markers analyzed plus FSC and SSC. Therapy-induced (phenotypic) clonal selection was further investigated by principal component analysis (PCA), based on the 25 parameters evaluated using the automated population separator (APS; principal component 1 vs. principal component 2) graphical representation of the Infinicyt software²⁰, and comparing merged patient-paired iPEP of baseline (diagnostic) vs. MRD myeloma PCs.

Copy number and gene expression profiling of baseline vs. MRD patient-paired myeloma PCs. Per-protocol, clonal PCs from diagnostic samples were isolated from BM aspirates using CD138⁺ immunomagnetic beads (Miltenyi Biotech, Bisley, UK). Following induction therapy, BM aspirates were obtained to determine patients' MRD response at cycle 9, and clonal PCs from MRD-positive cases were FACS-sorted (FACS Aria II, BDB; purity $\geq 97\%$) according to patient-specific aberrant phenotypes. DNA from matched diagnostic and MRD clonal PCs was available in 8/40 patients, as well as in 4 additional cases treated with six induction cycles with VRD, making a total of 12 patients. Afterwards, genome-wide detection of copy-number abnormalities (CNAs) and loss of heterozygosity (LOH) were investigated using the standard Affymetrix Cytoscan 750K platform (Affymetrix, Santa Clara, CA, USA). An unpaired analysis was performed using 240 Hapmap files as reference for normal DNA. The complete data set was analyzed by visual inspection using the AGCC and ChAS software programs (Affymetrix). CNAs were reported when the three following criteria were met: ≥ 25 consecutive imbalanced markers per segment; $\geq 100\text{Kb}$ minimum genomic size and; $< 50\%$ overlap with paired control DNA and/or genomic variants of Toronto DB (DGV).²⁷ Only copy number-neutral loss of heterozygosity (CNN-LOH) larger than 5Mb were considered.

Gene expression profiling (GEP) was performed in matched diagnostic and MRD clonal PCs from 7/40 cases with adequate RNA extracted from CD138⁺ and patient-specific phenotypically aberrant FACS-purified tumor cells, respectively. Briefly, the integrity of the extracted RNA was assessed using the Agilent 2100 Bioanalyzer. Afterward, RNA was amplified, labeled, and subsequently hybridized to the Human Gene 1.0 ST Array (Affymetrix).²⁸ Normalization was carried out by using the expression console (Affymetrix) with the RMA algorithm which includes background correction, normalization and calculation of expression values (\log_2).²⁹ The SIMFIT (<http://www.simfit.org.uk/>) statistical software was used to perform hierarchical clustering analyses based on Euclidean distances and the group average linkage method. Differentially expressed genes between classes were identified using the Significant Analysis of Microarrays (SAM) algorithm (<http://www-stat.stanford.edu/tibs/SAM>), and significant genes were selected based on the lowest q-value (< 0.05).^{28,29} We used the WebGestalt online suite³⁰ to identify the most relevant functional pathways involved according to the differentially expressed genes. Full microarray data is available at the Gene Expression Omnibus database (www.ncbi.nlm.nih.gov/geo/; accession number GSE70399). The potential impact on disease survival of selected top-deregulated genes was investigated in a series of newly-diagnosed MM patients who had been treated according to the Total Therapy

(TT) programs 3A (NCT00081939; n=276) and 3B (NCT00572169; n=168) with GEP data on CD138+ purified PCs. Optimal gene expression cut-offs were first established in patients enrolled in TT3A (training set), and then tested in patients enrolled in TT3B (validation set). Complete description of the TT3 program has been reported elsewhere.³¹

***In vitro* evaluation of ALCAM expression in chemoresistant MM cells.** Baseline levels of the ALCAM protein (CD166) (BDB) were assessed by flow cytometry on the surface of eight MM cell lines (NCI-H929, JJN3, KMS-11, MM1S, OPM2, RPMI-8226, U266, and U266-LR7). ALCAM expression was more extensively evaluated in RPMI-8226 MM cells after co-culture with BM stromal cells (BMSCs) with or without simultaneous exposure to bortezomib (5nM), lenalidomide (10µM), dexamethasone (1µM) and melphalan (1µM) for 24 and 48 hours at 37°C. Stromal cells were obtained as previously described³², and a confluent monolayer was generated by plating 10x10⁵ BMSCs in a 12-well plate for 48 hours. ALCAM expression was measured in chemoresistant (Annexin-V⁻) and chemosensitive (Annexin-V⁺) RPMI-8226 cells after exclusion of debris and cell doublets based on their FSC and SSC characteristics, and of CD38⁺CD138⁻ BMSCs. Data acquisition was performed in a FACSCantoII flow cytometer (BDB) using the FACSDiva 6.1 software (BDB); for data analysis the Infinicyt software (Cytognos) was used. All experiments were performed in triplicate.

Statistical analysis. The Wilcoxon signed rank test was used to evaluate the statistical significance of the phenotypic differences observed between baseline and MRD myeloma PCs, whereas the Mann-Whitney U and the Kruskal-Wallis tests were used to estimate the statistical significance of differences observed between two or more groups, respectively. The SPSS software (version 20.0; SPSS Inc., Chicago, IL, USA) was used for all statistical tests.

Results

MRD clonal PCs show a singular immunophenotypic protein expression profile (iPEP). The iPEP of clonal PCs from patient-paired diagnostic and MRD samples were analyzed in 40 patients. Compared to the diagnostic tumor bulk, chemoresistant MRD clonal PCs showed significant up-regulation ($P < .05$) of CD11a, CD11c, CD29, CD44, CD49d, CD49e, CD54, CD138, CXCR4 and HLADR (Figure 1A). Of note, differences in the expression levels of proteins were not due to *de novo* expression on MRD cells of previously undetectable antigens on diagnostic clonal PCs, but rather because the MRD clone clustered among those cells that at diagnosis showed the highest levels of expression for such markers (Figure 1B); in fact, MRD cells typically clustered in a more restricted area of that occupied by the whole BM clonal PC compartment at diagnosis (Figure 1B). Interestingly, differences in the ratio between the amount of antigen expressed per cell in paired MRD vs. diagnostic BM PCs for the top-5 deregulated markers were particularly evident in patients receiving only bortezomib, melphalan and prednisone (VMP) vs. those receiving alternating cycles of VMP and lenalidomide/dexamethasone (Rd) (Table 1); in fact, differential expression of markers such as CD81 ($P = .06$) and CD117 ($P = .03$) was noted among patients exposed only to VMP and not Rd. Altogether, these results suggest that between diagnosis and the MRD stage, therapy-induced phenotypic selection of clonal PCs might occur within the initial tumor bulk, in which PCs showing stronger expression of integrin and adhesion molecules are more prone to survive (Figure 1B).

Copy number profile of patient-paired diagnostic vs. MRD clonal PCs.

Comparison between iPEP of diagnostic vs. MRD clonal PCs suggested that the latter might represent a (phenotypic) subset of the whole diagnostic tumor population. In order to gain further insight into this novel hypothesis, we investigated copy number alteration (CNA) profiles of matched diagnostic vs. MRD clonal PCs (Figure 2). The median number of CNAs in diagnostic and MRD clonal PCs were 11 and 14, respectively. Individual patient analyses revealed that in three out of the twelve cases analyzed both clones showed identical copy number profiles (#1, #2, and #3), whereas in the remaining nine patients there were unique CNAs detected in at least one of the two PC populations. Namely, MRD clonal PCs from patients #4, #5, and #6 displayed all genetic alterations detected at diagnosis but one interstitial gain in chromosome 3 of patient #4, plus 4 and 5 additional CNAs that emerged at the MRD stage in cases #5 and #6, respectively (Figure 2). In the remaining six patients (#7 - #12) there was further variability, with both CNAs present at diagnosis that were undetectable in MRD clonal PCs, but also a selected number of genetic alterations that became apparent

only at the MRD stage (total of 4, 4, 4, 10, 14 and 17 different CNAs between diagnostic vs. MRD clonal PCs in patients #7, #8, #9, #10, #11 and #12, respectively). Overall, a total of 66 CNA (56 losses and 10 gains) were uniquely present in only one of the two PC populations (26 at diagnosis, and 40 after therapy), in the absence of recurrent patterns of genetic evolution from baseline into MRD cells. We also investigated the profile of copy number-neutral loss of heterozygosity (CNN-LOH) in matched diagnostic and chemoresistant clones. As expected, these abnormalities were less frequently observed and were only noted in 6 out of the 12 cases; in 3 of the latter 6 (#8, #9 and #12) the MRD clonal PCs lacked CNN-LOH present at diagnosis, whereas patient #6 had a CNN-LOH in chromosome 1 which was not detected at diagnosis. All remaining cases had overlapping CNN-LOH profiles.

Gene expression profiling of chemoresistant MRD clonal PCs. Upon demonstrating that chemoresistant MRD cells are characterized by a singular iPEP and they often carry CNAs which were undetectable at diagnosis or only became apparent after therapy, we sought to compare the gene expression profiling (GEP) of diagnostic vs. MRD clonal PCs in patient-paired (n=7) samples of the GEM2010MAS65 study, to determine whether chemoresistant subclones have unique GEP signatures. As a result, MRD clonal PCs showed deregulated expression of 1336 genes (317 up- and 1019 down-regulated) (Figure 3A and Supplementary Excel File 1). Functional analysis using all deregulated genes revealed that several of those being down-regulated, were related to cellular functions such as protein export, protein processing in the endoplasmic reticulum (ER), and N-Glycan biosynthesis (Table 2). In addition to down-regulation of a large number of ER-related genes, MRD clonal PCs also showed lower expression of genes encoding for different proteasome subunits (i.e.: *PAAF1*, *PSMA6*, *PSMB10*, *POMP*, *PSME1*, *PSMD10*, *PSMB6*, *PSME3*, *PSMA2*). Afterward, we focused on those genes that were maximally upregulated (fold-change ≥ 2) and downregulated (fold-change ≤ 0.5) in MRD vs. diagnostic clonal PCs, and that had been related to chemoresistance/aggressiveness in other neoplasms or related to proteasome-inhibition and ER stress (n=21 genes), and investigated their potential impact on the survival of newly-diagnosed MM patients enrolled in the Total Therapy program 3 (TT3) (Table 3). Overall, 9 out of the 21 genes tested showed a significant prognostic impact on overall survival (OS) in the training (TT3a) set, but only three of these nine genes kept their prognostic significance in the validation (TT3b) MM patient set; thus, inferior OS rates were observed in both series for cases showing overexpression of both *FLNA* (median OS of 5-years vs. not reached for patients with high vs. low *FLNA* expression, respectively; $P \leq .002$) (Supplementary Figure 2A) and *FERMT3* (median OS not

reached for patients with high vs. low *FERMT3* expression, respectively; $P = .03$) (Supplementary Figure 2B), as well as lower expression of *ALCAM* (median OS not reached vs. 6-years for patients with high vs. low *ALCAM* expression, respectively; $P \leq .02$) (Figure 3A). In line with the findings in newly-diagnosed patients enrolled in the TT3 program, the MRD clone in the GEM2010MAS65 trial also showed overexpression of *FERMT3* and *FLNA* plus downregulation of *ALCAM* vs. diagnostic PCs.

Since loss of *ALCAM* has been linked to more aggressive disease in different solid tumors, we further investigated its potential relationship with MM chemoresistance *in vitro*. *ALCAM* expression was found to be strong positive in the JJN3, KMS-11 and MM1S cell lines, dim positive in NCI-H929 and OPM2, and almost absent in the U266 and U266-LR7 cell lines (Figure 3B). RPMI-8266 MM cells showed heterogeneous *ALCAM* expression with two negative and positive subsets; thereby, we used this later cell line to investigate whether after drug exposure, chemoresistant (Annexin-V^{-ve}) MM cells would become enriched with the *ALCAM*^{-ve} subset as compared to chemosensitive (Annexin-V^{+ve}) PCs. Interestingly, the relative percentage of *ALCAM*^{-ve} cells within total RPMI-8226 MM cells was significantly increased (due to selective decrease of the *ALCAM*^{+ve} subset) among chemoresistant vs. chemosensitive PCs co-cultured with BMSCs and exposed *in vitro* to the combination of bortezomib, lenalidomide, dexamethasone and melphalan for 24/48 hours (median of 57% vs. 27%, respectively; $P = .003$) (Figure 3D). In fact, the increment in *ALCAM*^{-ve} cells was more pronounced when RPMI-8266 were exposed to all drugs administered simultaneously as compared to each drug individually (Supplementary Figure 3). Moreover, there was a trend towards progressively increased numbers of *ALCAM*^{-ve} MM cells within chemoresistant (Annexin-V^{-ve}) RPMI-8266 cells at baseline, after co-culture with BMSCs, and after exposure to chemotherapy (medians of 41%, 50% and 57%, respectively; $P = .09$) (Figures 3E and 3F). A similar pattern was noted upon comparing *ALCAM* expression in the chemoresistant KMS11/BTZ, U266-LR7 and MM1R cell lines vs. their chemosensitive counterparts (KMS11, U266 and MM1S) at baseline and upon co-culture with BMSCs (Supplementary Figure 4).

Discussion

Understanding MM genomic and molecular heterogeneity is required to develop treatment strategies that could target dominant but also subclonal reservoirs of chemoresistant cells. While clonal heterogeneity at diagnosis and clonal tiding from diagnosis to patients' relapse has been recently described^{15-17,21,33}, no attention has been paid to primary chemoresistant PCs that persist even among patients in serological response (i.e.: MRD). Since persistence of MRD is strongly linked to an inferior survival⁴⁻⁷, a better understanding of MRD clonal PCs is warranted to potentially overcome their chemoresistant phenotype. Here, we report for the first time the biologic features of MRD cells in MM. Overall, our results revealed that chemoresistant clones are enriched in cells with a distinct phenotypic signature, but also that there is frequent tiding of genetically different subclones. Ultimately, MRD PCs have a deregulated GEP which allows them to survive after multidrug chemotherapy.

In MM, disease recurrence after initial (complete) response to treatment has been typically hypothesized to be associated with more immature progenitor cells that escape conventional anti-myeloma therapy.^{18,34-36} Interestingly, while early studies suggested that persistent CD19⁺CD138⁻ clonotypic B-cells represented the MM cancer stem cell compartment and were responsible for disease relapse³⁴⁻³⁶, more recent data indicates that CD138⁺ PCs have a complex architecture linked to interconvertible phenotypic and functional compartments with different chemoresistant potential.^{18,21,37} In particular, it has been suggested that mature CD138⁺ PCs give rise to more immature CD138^{lo} pre-PCs/plasmablasts that secrete lower immunoglobulin levels (and are thereby less susceptible to ER stress)¹⁸ and could be specifically involved in disease dissemination.³⁷ In line with this hypothesis, we have recently shown that MM circulating tumor cells represent a singular phenotypic and functional subset of MM tumor cells characterized by lower CD138 expression^{22,38}. Here, we used new analytic tools developed by the EuroFlow Consortium²⁰ to simultaneously evaluate the pattern of expression of 23 markers at the single-cell level and longitudinally compare the iPEPs from diagnostic vs. MRD clonal PCs. In contrast to the above mentioned hypothesis, our results demonstrate that MM cells with stronger capacity to survive frontline chemotherapy were those with the highest expression of CD138; because MRD clonal PCs are responsible for the disease relapse, these results point out the clonogenic potential of mature CD138⁺ PCs. Furthermore, MRD subclones showed enhanced expression of several integrins (e.g.: CD11a, CD11c, CD29, CD49d, CD49e), chemokine receptors (e.g.: CXCR4) and adhesion molecules (e.g.: CD44 and CD54), CD28 (a pro-survival mediator through PC-dendritic cell interaction³⁹) and

HLADR. The expression of these class of markers has been shown to be intrinsically related to different PC chemoresistant potential *in vitro* and *in vivo*⁴⁰⁻⁴⁵, as well as to patients' survival⁴⁶⁻⁴⁸, which would be potentially due to a stronger attachment of MRD clonal PCs to the BM stroma, which provides higher protection from chemotherapy-induced apoptosis.^{49,50} In fact, it could be hypothesized that a subset of chemoresistant MRD cells strongly attached to the stroma might be potentially underestimated in BM aspirates. By contrast, a different role has been assigned to CD44 in cell-adhesion mediated drug resistance (CAM-DR) in several cancers including MM, where CD44 may partially contribute to dexamethasone resistance⁵¹ and becomes upregulated in lenalidomide-resistant MM cells to stabilize the expression of P-glycoprotein, a multi-drug resistance efflux pump responsible for the cellular uptake of lenalidomide.^{13,52} Interestingly, differences between diagnostic vs. MRD cells were more pronounced among patients treated only with VMP vs. cases exposed to VMP and Rd. Altogether, these findings suggest that from a phenotypic standpoint, chemoresistant PCs represent a uniquely defined subclone of all diagnostic tumor cells, but also that the more drugs being simultaneously used the higher the chances to debulk all different phenotypic tumor subclones. Further studies are warranted to confirm if the enhanced expression of integrins in MRD clonal PCs is biologically meaningful; *in vitro*, we noted that chemoresistant myeloma cell lines slightly increase their expression of CD11c, CD29, CD44, and CD49d and CD49e upon short-term (24h) co-culture with BMSCs (Supplementary Figure 5).

Longitudinal comparison between the genomic profiles of PCs studied at diagnosis and during patients' relapse has revealed three models of clonal dynamics: genetic stability over time, acquired CNAs at relapse, or heterogeneous fluctuation of different genetic clones from earlier to later time-points.^{16,53} Here, we show that such genetic instability is already detectable at the MRD level, with three out of twelve cases analyzed showing identical copy number profiles whereas in the remaining patients there was a median of 4 different CNAs between diagnostic vs. MRD clonal PCs. However, it is unlikely that all the differences observed were acquired upon treatment exposure; instead, it is most likely that a significant number of such CNAs are present at subclonal levels, but because the methodology used in the present study can only detect abnormalities that are present in 20% or more of clonal PCs cells¹⁷, they may have gone undetected (Supplementary Figures 6 and 7). Altogether, these findings are of high relevance since they illustrate that small subclones carrying unique cytogenetic abnormalities may become the predominant population after chemotherapy, and according to the specific type of genetic alteration acquired or lost, influence patients' prognosis. Longitudinal analyses between diagnostic vs MRD vs relapse patient-paired

samples are now warranted to understand if the clonal distribution of PCs at MRD mimics that of relapse, or if additional changes are observed between both time-points. Accordingly, our observations suggest that monitoring of MM patients should become more comprehensive, not only gathering information on MRD levels to determine the depth of response, but also combining it with the cytogenetic characterization of MRD cells to better understand their malignant potential and identify potential therapeutic targets.²¹ In this regard, we have also hypothesized that understanding the molecular signature of MRD cells could contribute to the discovery of novel genes/pathways which are responsible for drug resistance in individual patients. Thus, comparison of the GEP of patient-paired diagnostic vs. MRD cells revealed over 1.000 deregulated genes, several of which are related to protein export, protein processing, and N-Glycan biosynthesis. These findings are consistent with those reported by Leung-Hagesteijn et al¹⁸, who showed that PCs with lower protein production have lower ER protein-load rendering them less vulnerable to lethal ER stress induced by proteasome inhibitors. *In vitro* studies have also reported similar observations in which attenuation of the eukaryotic initiation factor (eIF)-2 α phosphorylation and ER stress were required for MM cells to survive proteasome inhibition^{10,54-56}; accordingly, MRD clonal PCs showed significant down-regulation of different eIF-related genes (Supplementary Excel File 1). One potential caveat of the present study is the sole focus on clonal and mature PCs, since the MRD compartment may also reside among CD138⁻ cells that are expected to have lower expression of ER-genes.¹⁸ However, our experience on the comparison of MRD levels determined by MFC (that focus on the CD138⁺ PC compartment) vs. molecular methods (that measure clonotypic VDJ rearrangements in whole BM samples), shows a highly significant correlation between the number of MRD cells detected by both techniques.^{4,6} Accordingly, if CD138⁻ MRD “stem cells” exist, they would be present at levels $<10^{-6}$ and therefore, virtually impossible to identify and study using current technology.

The transcriptomic characterization of chemoresistant tumor cells might represent a different strategy to identify novel molecular pathways potentially related to patients' outcome. Accordingly, mRNA expression levels in newly-diagnosed MM patients of three of the top-deregulated genes in MRD clonal PCs (*FERMT3*, *FLAN* and *ALCAM*) were of significant prognostic value, suggesting that patients with a PC compartment that at diagnosis was potentially enriched in chemoresistant cells have inferior overall survival. Noteworthy, such genes have been previously linked to more aggressive phenotypes in solid tumors but not in MM. In line with the singular iPEP of MRD clonal PCs potentially favoring their attachment to the BM stroma, *FERMT3* and *FLNA* have been assigned a role in integrin activation and cell migration, respectively.

Similarly, *ALCAM* has been implicated in cell migration and invasion in melanoma as well as several other tumors including those of the prostate, esophagus, colon, bladder, pancreas and lung.⁵⁷ Interestingly, in an *in vitro* model where MM cells co-cultured with BMSCs were exposed to the same drugs as the MRD clone from patients enrolled in the GEM2010MAS65 trial, a progressive accumulation of *ALCAM*^{-ve} cells among chemoresistant cells was observed. Thus, the understanding of the molecular signature of MRD cells along with the investigation of whether these cells were detectable before treatment (intrinsic resistant cells) or not (acquired resistant cells) will hopefully provide novel insight into the field of chemoresistance in MM; that notwithstanding, such knowledge is most likely treatment-dependent, since different molecular pathways will potentially emerge from the study of MRD cells after different treatment strategies. Thus, the results of the GEP comparison between patient-paired diagnostic vs. chemoresistant MRD clonal PCs, herein performed in a limited number of cases, should be interpreted as hypothesis generating rather than conclusive. This also applies for *ALCAM*, and further studies in larger series of patients are warranted to confirm this hypothesis.

In summary, by characterizing patient-paired diagnostic vs. MRD clonal PCs we unravel that therapy-induced clonal selection is already present at the MRD stage, in which chemoresistant myeloma PCs show a specific phenotypic signature that may result from the persistence of subclones with different cytogenetic and gene expression profiles. Characterization of the MRD clone may represent a unique model for a better understanding of chemoresistance and the characteristics of the cellular source of relapses after response to front-line therapy, and ultimately design therapeutic strategies to overcome resistance already at the MRD stage.

Acknowledgments: The authors want to acknowledge all the participants of the Spanish Myeloma Group.

Financial support: This study was supported by the Cooperative Research Thematic Network grants RD12/0036/0048, RD12/0036/0058, RD12/0036/0046, RD12/0036/0069 of the Red de Cancer (Cancer Network of Excellence); Instituto de Salud Carlos III, Spain, Instituto de Salud Carlos III/Subdirección General de Investigación Sanitaria (FIS: PI060339; 06/1354; 02/0905; 01/0089/01-02; PS09/01897/01370; G03/136; Sara Borrell: CD13/00340); and Asociación Española Contra el Cáncer (GCB120981SAN), Spain. The study was also supported internationally by the International Myeloma Foundation (IMF) Junior Grant, the Black Swan Research Initiative of the IMF, the Multiple Myeloma Research Foundation (MMRF) research fellow award, the Qatar National Research Fund (QNRF) Award No. 7-916-3-237, the AACR-Millennium Fellowship in Multiple Myeloma Research (15-40-38-PAIV), and the European Research Council (ERC) 2015 Starting Grant.

Authorship Contributions

Conception and design: BP, JJJ and JFSM

Development of methodology: BP, LAC, PM, IR, DA, LB, MLS, PB, AO, SKJ, JE

Acquisition of data: BP, LAC, MBV, PM, IR, DA, MLS, PB, MAE, MTH, RGS, EMO, NP, AO, MG, LP, FdA, YG, JJJ, JB, AO, SKJ, JE, BB, MVM, JFSM

Analysis and interpretation of data: BP, LAC, PM, AO, JE, BB, MVM, JFSM

Writing, review and/or revision of the manuscript: BP and JFSM wrote the manuscript.

All authors reviewed the manuscript.

Disclosure of Conflicts of interest: The authors declare no conflict of interest.

References

1. Paiva B, van Dongen JJ, Orfao A. New criteria for response assessment: Role of minimal residual disease in multiple myeloma. *Blood*. 2015;125(20):3059-3068.
2. Moreau P, Attal M, Facon T. Frontline therapy of multiple myeloma. *Blood*. 2015;125(20):3076-3084.
3. Barlogie B, Mitchell A, van Rhee F, Epstein J, Morgan GJ, Crowley J. Curing myeloma at last: Defining criteria and providing the evidence. *Blood*. 2014;124(20):3043-3051.
4. Puig N, Sarasquete ME, Balanzategui A, et al. Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry. *Leukemia*. 2014;28(2):391-7.
5. Paiva B, Gutierrez NC, Rosinol L, et al. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. *Blood*. 2012;119(3):687-91.
6. Martinez-Lopez J, Lahuerta JJ, Pepin F, et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. *Blood*. 2014;123(20):3073-9.
7. Rawstron AC, Gregory WM, de Tute RM, et al. Minimal residual disease in myeloma by flow cytometry: Independent prediction of survival benefit per log reduction. *Blood*. 2015;125(12):1932-1935.
8. San Miguel J. Multiple myeloma: A model for scientific and clinical progress. *Hematology Am Soc Hematol Educ Program*. 2014;2014(1):1-7.
9. Ri M, Iida S, Nakashima T, et al. Bortezomib-resistant myeloma cell lines: A role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress. *Leukemia*. 2010;24(8):1506-1512.
10. Schewe DM, Aguirre-Ghiso JA. Inhibition of eIF2alpha dephosphorylation maximizes bortezomib efficiency and eliminates quiescent multiple myeloma cells surviving proteasome inhibitor therapy. *Cancer Res*. 2009;69(4):1545-1552.
11. Zhu YX, Braggio E, Shi CX, et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. *Blood*. 2011;118(18):4771-4779.
12. Gandhi AK, Mendy D, Waldman M, et al. Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity. *Br J Haematol*. 2014;164(2):233-244.

13. Bjorklund CC, Baladandayuthapani V, Lin HY, et al. Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: Therapeutic implications. *Leukemia*. 2014;28(2):373-383.
14. Ocio EM, Fernandez-Lazaro D, San-Segundo L, et al. In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone. *Leukemia*. 2015;29(3):705-714.
15. Lohr JG, Stojanov P, Carter SL, et al. Widespread genetic heterogeneity in multiple myeloma: Implications for targeted therapy. *Cancer Cell*. 2014;25(1):91-101.
16. Bolli N, Avet-Loiseau H, Wedge DC, et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. *Nat Commun*. 2014;5:2997.
17. Magrangeas F, Avet-Loiseau H, Gouraud W, et al. Minor clone provides a reservoir for relapse in multiple myeloma. *Leukemia*. 2013;27(2):473-481.
18. Leung-Hagesteijn C, Erdmann N, Cheung G, et al. Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. *Cancer Cell*. 2013;24(3):289-304.
19. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. *Leukemia*. 2006;20(9):1467-73.
20. Kalina T, Flores-Montero J, van der Velden VH, et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. *Leukemia*. 2012;26(9):1986-2010.
21. Paino T, Paiva B, Sayagues JM, et al. Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential. *Leukemia*. 2015;29(5):1186-1194.
22. Paiva B, Paino T, Sayagues JM, et al. Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile. *Blood*. 2013;122(22):3591-3598.
23. Cover TM HP. Nearest neighbor pattern classification. *IEEE Trans Inf Theory*. 1967;13:21-27.
24. Duda RO, Hart PE, Stork DG. *Pattern classification*. New York, NY: Wiley; 2001.
25. Pedreira CE, Costa ES, Barrena S, et al. Generation of flow cytometry data files with a potentially infinite number of dimensions. *Cytometry A*. 2008;73(9):834-846.
26. Pedreira CE, Costa ES, Lecrevisse Q, van Dongen JJ, Orfao A, EuroFlow Consortium. Overview of clinical flow cytometry data analysis: Recent advances and future challenges. *Trends Biotechnol*. 2013;31(7):415-425.
27. Zhang J, Feuk L, Duggan GE, Khaja R, Scherer SW. Development of bioinformatics resources for display and analysis of copy number and other structural variants in the human genome. *Cytogenet Genome Res*. 2006;115(3-4):205-214.

28. Lopez-Corral L, Corchete LA, Sarasquete ME, et al. Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies. *Haematologica*. 2014;99(8):1365-1372.
29. Gutierrez NC, Ocio EM, de Las Rivas J, et al. Gene expression profiling of B lymphocytes and plasma cells from waldenstrom's macroglobulinemia: Comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals. *Leukemia*. 2007;21(3):541-549.
30. Wang J, Duncan D, Shi Z, Zhang B. WEB-based GENE SeT ANALYSIS toolkit (WebGestalt): Update 2013. *Nucleic Acids Res*. 2013;41(Web Server issue):W77-83.
31. Usmani SZ, Sawyer J, Rosenthal A, et al. Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma. *Blood*. 2013;121(23):4753-4757.
32. Maiso P, Liu Y, Morgan B, et al. Defining the role of TORC1/2 in multiple myeloma. *Blood*. 2011;118(26):6860-6870.
33. Schmidt-Hieber M, Gutierrez ML, Perez-Andres M, et al. Cytogenetic profiles in multiple myeloma and monoclonal gammopathy of undetermined significance: A study in highly purified aberrant plasma cells. *Haematologica*. 2013;98(2):279-287.
34. Matsui W, Huff CA, Wang Q, et al. Characterization of clonogenic multiple myeloma cells. *Blood*. 2004;103(6):2332-2336.
35. Peacock CD, Wang Q, Gesell GS, et al. Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. *Proc Natl Acad Sci U S A*. 2007;104(10):4048-4053.
36. Pilarski LM, Baigorry E, Mant MJ, et al. Multiple myeloma includes phenotypically defined subsets of clonotypic CD20+ B cells that persist during treatment with rituximab. *Clin Med Oncol*. 2008;2:275-287.
37. Chaidos A, Barnes CP, Cowan G, et al. Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma. *Blood*. 2013;121(2):318-328.
38. Paiva B, Perez-Andres M, Vidriales MB, et al. Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma. *Leukemia*. 2011;25(4):697-706.
39. Murray ME, Gavile CM, Nair JR, et al. CD28-mediated pro-survival signaling induces chemotherapeutic resistance in multiple myeloma. *Blood*. 2014;123(24):3770-3779.
40. Canella A, Cordero Nieves H, Sborov DW, et al. HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide. *Oncotarget*. 2015;6(31):31134-31150.

41. Iqbal MS, Otsuyama K, Shamsasenjan K, et al. Constitutively lower expressions of CD54 on primary myeloma cells and their different localizations in bone marrow. *Eur J Haematol*. 2009;83(4):302-312.
42. Noborio-Hatano K, Kikuchi J, Takatoku M, et al. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma. *Oncogene*. 2009;28(2):231-242.
43. Shain KH, Yarde DN, Meads MB, et al. Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: Implications for microenvironment influence on tumor survival and proliferation. *Cancer Res*. 2009;69(3):1009-1015.
44. Martinez-Vinambres E, Garcia-Trujillo JA, Rodriguez-Martin E, Villar LM, Coll J, Roldan E. CD29 expressed on plasma cells is activated by divalent cations and soluble CD106 contained in the bone marrow plasma: Refractory activation is associated with enhanced proliferation and exit of clonal plasma cells to circulation in multiple myeloma patients. *Leukemia*. 2012;26(5):1098-1105.
45. Neri P, Ren L, Azab AK, et al. Integrin beta7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion. *Blood*. 2011;117(23):6202-6213.
46. Kurata M, Nakagawa Y, Yamamoto K, Suzuki K, Kitagawa M. Induction of integrin beta1 expression in bone marrow cells after chemotherapy correlates with the overexpression of lung resistance protein and poor outcome in patients with multiple myeloma. *Am J Hematol*. 2008;83(9):755-757.
47. Stessman HA, Mansoor A, Zhan F, et al. Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib. *Leukemia*. 2013;27(10):2075-2077.
48. Mateo G, Montalban MA, Vidriales MB, et al. Prognostic value of immunophenotyping in multiple myeloma: A study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy. *J Clin Oncol*. 2008;26(16):2737-2744.
49. Garayoa M, Garcia JL, Santamaria C, et al. Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors. *Leukemia*. 2009;23(8):1515-1527.
50. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. *Nat Rev Cancer*. 2007;7(8):585-598.
51. Ohwada C, Nakaseko C, Koizumi M, et al. CD44 and hyaluronan engagement promotes dexamethasone resistance in human myeloma cells. *Eur J Haematol*. 2008;80(3):245-250.

52. Hofmeister CC, Yang X, Pichiorri F, et al. Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: Evidence for lenalidomide-CCI-779 interaction via P-glycoprotein. *J Clin Oncol*. 2011;29(25):3427-3434.
53. Melchor L, Brioli A, Wardell CP, et al. Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma. *Leukemia*. 2014;28(8):1705-1715.
54. Tagoug I, Jordheim LP, Herveau S, et al. Therapeutic enhancement of ER stress by insulin-like growth factor I sensitizes myeloma cells to proteasomal inhibitors. *Clin Cancer Res*. 2013;19(13):3556-3566.
55. Chauhan D, Tian Z, Zhou B, et al. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. *Clin Cancer Res*. 2011;17(16):5311-5321.
56. Thakurta A, Gandhi AK, Waldman MF, et al. Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy. *Leukemia*. 2014;28(5):1129-1131.
57. King JA, Tan F, Mbeunkui F, et al. Mechanisms of transcriptional regulation and prognostic significance of activated leukocyte cell adhesion molecule in cancer. *Mol Cancer*. 2010;9:266-4598-9-266.

Table 1. iPEP of diagnostic vs. MRD BM (clonal) PCs in MM patients (n=40) studied after induction therapy (9 cycles of VMP vs. 9 alternating cycles of VMP and RD); the fold-change in the ratio between the amount of protein per PC (MFI) for paired MRD / diagnostic BM clonal PCs is shown for the top-5 markers over-expressed on MRD cells in the overall patient series, and the two different patient treatment groups. All markers were evaluated in all 40 patients at both time-points (diagnosis vs. MRD).

	Overall series (n=40)		Sequential chemotherapy (n=21)		Alternating chemotherapy (n=19)	
Markers	Fold-change	<i>P</i> -value	Fold-change	<i>P</i> -value	Fold-change	<i>P</i> -value
CD29	1.95	<.001	1.95	<.001	2.02	.009
CD54	1.92	<.001	2.98	<.001	1.31	.04
CD138	1.90	.04	2.16	.03	1.22	.36
CD44	1.79	<.001	2.04	<.001	1.50	.008
CD49e	1.58	<.001	1.97	.002	1.49	.084

MFI: mean fluorescence intensity; PCs: plasma cells; VMP: bortezomib, melphalan, prednisone; Rd: lenalidomide, dexamethasone; CR: complete response; VGPR: very good partial response; PR: partial response

Table 2. Selected pathways and transcription targets predicted to be significantly inhibited according to the corresponding deregulated genes in patient-paired diagnostic vs, minimal residual disease (MRD) clonal plasma cells (PCs).

		<i>P</i> -value	Genes down- or <u>up</u> - regulated in MRD clonal PCs
Pathways	Protein export	1.50e-05	SRPRB, SRP72, SEC61A1, SEC61G, SRP68, SPCS1, SEC11C, SPCS2, SPCS3, SEC63
	Protein processing in endoplasmic reticulum	1.50e-05	ERLEC1, SEC61G, MAN1A2, DNAJB11, SSR2, UGGT1, SEC63, EDEM2, CANX, SEC23B, OS9, SSR1, DERL1, SAR1B, RPN1, SEC61A1, STT3A, DERL2, DAD1, UBE2J1, SEL1L, EIF2S1, SSR3, LMAN2, UBE2G1, LMAN1, PDIA6
	N-Glycan biosynthesis	0.0004	<u>MAN2A2</u> , RPN1, ALG5, DPM1, STT3A, ALG14, ALG13, MAN1A2, DAD1, ALG8, DOLK, ALG1
Transcription targets			
	ELK1	1.91e-06	ZNF35, TOMM20, YIPF5, PYROXD1, <u>TRAF7</u> , F11R, POMP, <u>SND1</u> , TMEM167A, HCCS, BECN1, MTMR2, UBLCP1, C14orf119, PHF5A, UBA2, DNAAF2, ATXN10, ACVR2A, RNF2, <u>DNMT1</u> , DDX1, RNF185, <u>U2AF2</u> , SLC39A9, RWDD2A, DPM1, UXT, TLK1, SDF2, TMEM59, GTF2A2, JAGN1, <u>UBR4</u> , NECAP2, AMZ2, TMCO1, WAS, DSCR3, <u>TBCC</u> , SEC61A1, C21orf59, ZBTB41, <u>GMIP</u> , <u>E2F4</u> , PEX2, POLR2H, MAD2L1BP, C11orf57, <u>YEATS2</u> , NXT2, CCDC25, <u>UNC13D</u> , MKI67IP, NDUFS1, PIGW, ZCCHC9, MUT, C17orf80, PHB2, ITFG1, UFC1, CBLL1, SDHAF2, UGGT1, <u>HNRNPH1</u> , SLC35A5, EIF1AD, GRPEL2, <u>CEP164</u> , ERH, LSM5, <u>SHKBP1</u> , VMP1, TMEM62, FTSJD1, COX6A1, <u>BANF1</u> , RPL27, FBXO38, MEA1, CKS1B, HARS2, LMAN2, MORN2, MRPL40, TOMM70A, ZNF184, <u>MAP4K2</u> , RHOA, <u>PGS1</u> , CALU, ZSCAN12, UFM1, TRMT112, TGDS, FANCF, RNF13, THUMPD3, COX17, ZFP3, RPL32, PALB2, MRPL33, <u>LYL1</u> , <u>COX8A</u> , EIF2S1, PITPNA, TXNDC12, PSME3, MRPL3

Table 3. Deregulated genes in patient-paired minimal residual disease (MRD) vs. diagnostic clonal plasma cells (PCs) and their prognostic value according to mRNA expression levels in PCs from newly-diagnosed patients treated according to Total Therapy (TT) programs 3A (training set) and 3B (validation set).

Genes	Expression in MRD vs. diagnostic clonal PCs	Expression in TT3 patients	TT3A (training set)		TT3B (validation set)	
			Median (years)	P-value	Median (years)	P-value
Cancer related						
<i>FERMT3</i>	(↑)	> 9.8 ≤ 9.8	NR NR	.03	NR NR	.03
<i>TSPO</i>	(↑)	> 11.55 ≤ 11.55	7y NR	.06	3y NR	.0002
<i>ALOX5</i>	(↑)	> 12.39 ≤ 12.39	NR NR	.07	NR NR	.11
<i>NCF4</i>	(↑)	> 10.58 ≤ 10.58	NR NR	.09	7y NR	.2
<i>FLNA</i>	(↑)	> 10.56 ≤ 10.56	7y NR	.0002	6y NR	.003
<i>PREX1</i>	(↑)	> 5.33 ≤ 5.33	NR 7y	.02	NR NR	.79
<i>PYCARD</i>	(↑)	> 9.37 ≤ 9.37	9y NR	.001	NR NR	.35
<i>MYO1G</i>	(↑)	> 4.66 ≤ 4.66	NR 7y	.01	NR NR	.09
<i>SERPINI1</i>	(↓)	> 9.85 ≤ 9.85	NR NR	.11	NR NR	.47
<i>DUSP11</i>	(↓)	> 11.04 ≤ 11.04	NR NR	.06	NR NR	.86
<i>ALCAM</i>	(↓)	> 10.29 ≤ 10.29	NR 5y	.0002	NR 6y	.02
<i>CCNC</i>	(↓)	> 11.71 ≤ 11.71	NR 9y	.07	NR NR	.67
<i>COPZ1</i>	(↓)	> 11.29 ≤ 11.29	NR NR	.38	NR NR	.71
<i>FZD3</i>	(↓)	> 9.20 ≤ 9.20	NR 9y	.01	NR NR	.18
<i>E2F5</i>	(↓)	> 9.92 ≤ 9.92	9y NR	.10	NR NR	.88
ER related						
<i>PDIA5</i>	(↓)	> 11.76 ≤ 11.76	NR 9y	.17	NR NR	.10
<i>EMC7</i>	(↓)	> 13.72 ≤ 13.72	9y NR	.11	7y NR	.77
PI related						
<i>PSMD10</i>	(↓)	> 10.68 ≤ 10.68	9y NR	.003	NR NR	.25
<i>SMILE/TMTC3</i>	(↓)	> 4.0 ≤ 4.0	NR 9y	.08	NR 6y	.06
<i>PSME3</i>	(↓)	> 8.69 ≤ 8.69	NR NR	.03	NR NR	.33
<i>PSMB6</i>	(↓)	> 12.42 ≤ 12.42	9y NR	.11	NR NR	.07
<i>CAV1</i>	(↓)	> 12.46 ≤ 12.46	7y NR	.11	NR NR	.43

NR: not reached

Figure legends.

Figure 1. (A) Immunophenotypic protein expression profiles (iPEP) of MRD vs. diagnostic MM clonal PCs (n=40). Detailed immunophenotypic features of paired diagnostic versus minimal residual disease (MRD) clonal plasma cells (PCs) from 40 multiple myeloma (MM) patients. All markers were evaluated in all 40 cases at both time-points (diagnosis vs. MRD). Notched boxes represent the 25th and 75th percentile values of the ratio between the amount of antigen MFI expression per paired MRD / diagnostic BM clonal PCs; the line in the middle and vertical lines correspond to the median value and both the 10th and 90th percentiles, respectively. **(B)** Representative bivariate dot-plots for the top 5 over-expressed markers in MRD versus diagnostic BM clonal PCs are shown (CD29, CD54, CD138, CD44, CD49e), as well as the corresponding immunophenotypic protein expression profiles (iPEP) for each of the five representative patients. The iPEP of diagnostic BM clonal PCs is represented by one and two standard deviation lines, whereas their paired individual MRD cells are represented by black dots. Each patient-specific iPEP is represented using the automated population separator (APS1) plot based on a graphical representation of principal component 1 (x-axis) vs. principal component 2 (y-axis) for a total of 25 parameters.

Figure 2. Clonal evolution from diagnosis to MRD clonal PCs. (A) Overview of copy number alterations (CNAs) and **(B)** copy number neutral loss of heterozygosity (CNN-LOH) detected in clonal plasma cells (PCs) from matched bone marrow samples from 12 patients at diagnosis and during MRD monitoring. In Panel A, copy number profile of patient-paired diagnostic and MRD clonal PCs for each patient are stacked, with the diagnostic sample shown on the top (green) and the MRD sample in the bottom (brown). Sample pairs are indicated on the y-axis and chromosome location on the x-axis. Blue shading indicates the presence of copy number loss, red indicates copy number gain. In panel B, CNN-LOH detected in diagnostic (in salmon) and MRD (blue) clonal PCs are represented by pink bars.

Figure 3. Gene expression profiles of MRD vs diagnostic MM clonal PCs. (A) Heat map of genes with differential expression (FDR q-value <0.05) between patient-paired diagnostic vs. MRD clonal PCs. **(B)** Overall survival according to low vs. high (≤ 10.29 vs. > 10.29 normalized mRNA expression) ALCAM levels determined in CD138+ve purified plasma cells (PCs) from newly-diagnosed multiple myeloma (MM) patients treated according to the Total Therapy (TT) program 3A (n=276; training set) and 3B (n=168; validation set). **(C)** ALCAM (CD166) protein surface expression in a panel of

MM cell lines is shown using the total density graphic representation of the Infinicyt software. **(D)** Overall ALCAM (CD166) protein surface expression in chemoresistant (Annexin-V^{-ve}) and apoptotic (Annexin-V^{+ve}) RPMI-8226 cells; the percentage of ALCAM^{-ve} and ALCAM^{+ve} MM cells is represented by the black and grey bars, respectively **(E)** Percentage of ALCAM^{-ve} cells within total chemoresistant (Annexin-V^{-ve}) RPMI-8226 cells at baseline, upon co-culture with bone marrow stromal cells (BMSCs), and in co-culture with BMSCs after 24h and 48h exposure to bortezomib, lenalidomide, dexamethasone and melphalan. All experiments were performed in triplicate. **(F)** Representative experiment (n=1) of ALCAM (CD166) protein surface expression in chemoresistant (Annexin-V^{-ve}) RPMI-8226 cells.